WO2025016444 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1
National phase entry is expected:
Publication Number
WO/2025/016444
Publication Date
23.01.2025
International Application No.
PCT/CN2024/106291
International Filing Date
19.07.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1
[French]
COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE PD-L1
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/108449
20.07.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4095 | |
| EPO | Filing, Examination, Granting | 66124 | |
| Japan | Filing, Examination, Granting | 4081 | |
| South Korea | Filing, Examination, Granting | 6187 | |
| USA | Filing, Examination, Granting | 20190 |
Total:
100,677
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of PD-L1 gene and for treatment of PD-L1-associated diseases and conditions are provided. Provided are PD-L1 dsRNA agents, PD-L1 antisense polynucleotide agents, compositions comprising PD-L1 dsRNA agents, and compositions comprising PD-L1 antisense polynucleotide agents that can be used to reduce PD-L1 expression in cells and subjects.[French]
L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène PD-L1 et pour le traitement de maladies et d'états associés à PD-L1. L'invention concerne des agents ARNdb PD-L1, des agents polynucléotidiques antisens PD-L1, des compositions comprenant des agents ARNdb PD-L1, et des compositions comprenant des agents polynucléotidiques antisens PD-L1 qui peuvent être utilisés pour réduire l'expression de PD-L1 chez des cellules et des sujets.